Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viracept in liposarcoma
NCT00233948Phase 2Terminated
- Sponsor
- City of Hope
- Start
- Mar 2006
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nelfinavir in Liposarcoma, sponsored by City of Hope. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Started Mar 2006; status: terminated.
02
Drugs
nelfinavir
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on NCT00233948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00233948.